Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

46.75
+1.914.26%
Post-market: 46.50-0.2500-0.53%19:30 EDT
Volume:4.08M
Turnover:190.12M
Market Cap:7.77B
PE:-13.43
High:47.42
Open:46.68
Low:45.75
Close:44.84
52wk High:86.74
52wk Low:44.66
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.79
T/O Rate:2.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:17.67
PE(LYR):-19.63

Loading ...

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza Available in 50 Mg or 80 Mg Dose, Self-administered Monthly

THOMSON REUTERS
·
Jun 25

Tryngolza® (olezarsen) Approved by the FDA as the First and Only Treatment to Reduce Triglycerides and the Risk of Acute Pancreatitis in Patients with Severe Hypertriglyceridemia (shtg)

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza to be Available in U.S. for Shtg in July

THOMSON REUTERS
·
Jun 25

FDA: Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia

THOMSON REUTERS
·
Jun 25

Ionis' Tryngolza Receives FDA Approval to Treat Acute Pancreatitis in Severe Hypertriglyceridemia Patients

MT Newswires Live
·
Jun 25

FDA announces approval of Ionis’ Tryngolza for hypertriglyceridemia

TIPRANKS
·
Jun 24

How Olezarsen’s Longer-Term Hepatic Data and High Retention Could Shape Ionis Pharmaceuticals (IONS) Investors

Simply Wall St.
·
Jun 20

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

InvestorPlace
·
Jun 19

Ionis Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 17

U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower

Reuters
·
Jun 17

Ionis director Spencer R. Berthelsen sells 8,000 shares worth $587,920

Reuters
·
Jun 17

Jefferies Remains a Buy on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jun 15

Ionis posts presentation on olezarsen-triglyceride reductions in severe hypertriglyceridemia

Reuters
·
Jun 15

Ionis posts ENDO 2026 presentation on olezarsen pancreatitis prevention in severe hypertriglyceridemia

Reuters
·
Jun 15

Ionis posts CORE-TIMI severe hypertriglyceridemia olezarsen data presentation

Reuters
·
Jun 13

Ionis shares 24-month extension data on olezarsen in severe hypertriglyceridemia study

Reuters
·
Jun 13

Fonds de solidarité FTQ joins $20 million CELYSTRA Pharma financing round

Reuters
·
Jun 09

Ionis Pharmaceuticals director Peter N. Reikes files initial beneficial ownership statement

Reuters
·
Jun 09